The European Medicines Agency has concluded that rare atypical fractures of the femur are a class effect of bisphosphonate drugs. The Agency's Committee for Medicinal Products for Human Use (CHMP) said that whilst the drugs' benefits still outweigh their risks in the treatment of osteoporosis, a warning of the risk of these fractures should be added to prescribing information.

Full article